Ward J. 2001. APERT study: systemic and local reactions. E-mail to Edwards K, Joellenbeck L, Institute of Medicine Committee to Assess the Safety and Efficacy of the Anthrax Vaccine, Washington, D.C., February 8.

Weiss R. 2001, September 29. Demand growing for anthrax vaccine: fear of bioterrorism attack spurs requests for controversial shot. Washington Post. p. A16.

Westblom TU, Gudipati S, DeRousse C, Midkiff BR, Belshe RB. 1994. Safety and immunogenicity of an inactivated hepatitis A vaccine: effect of dose and vaccination schedule. Journal of Infectious Diseases 169(5):996–1001.

Wright GG, Green TW, Kanode RG Jr. 1954. Studies on immunity in anthrax. V. Immunizing activity of alum-precipitated protective antigen. Journal of Immunology 73:387–391.

Yamamoto S, Kuroki T, Kurai K, Iino S. 1986. Comparison of results for phase I studies with recombinant and plasma-derived hepatitis B vaccines, and controlled study comparing intramuscular and subcutaneous injections of recombinant hepatitis B vaccine. Journal of Infection 13(Suppl A):53–60.

The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement